Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 16, 2003. The report serves to disclose specific changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) held through employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting share transactions and does not contain financial performance data.
Material Changes
- Employee Share Option Plan: On June 12, 2003, the GlaxoSmithKline Employee Trust transferred 10,124 Ordinary Shares to a participant in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On June 12, 2003, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,714,907 to 18,702,194. This reduction occurred at an average price of $41.80.
Management Commentary and Risks
Management notes that Directors Dr. J-P Garnier and Mr. J D Coombe are interested in the shares held in the GSK Trust, while Dr. J P Garnier is potentially interested in the shares held in the US Retirement Savings Plan. These interests are held in the same capacity as other employees or former employees of GlaxoSmithKline plc and its subsidiaries. No other risks, contingencies, or unusual items are disclosed in this filing.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust and the US Retirement Savings Plan to assess the scale of director exposure relative to total outstanding shares.
- Confirm the specific identity of the participant who received the 10,124 shares under the 1991 Employee Share Option Plan.
- Review the broader 20-F annual report for comprehensive financial performance data, as this 6-K filing contains no financial metrics.